Skip to content
ANG Lifesciences logo

ANG Lifesciences

540694 BSE
Price unavailable

ANG Lifesciences (ANG) share price was ₹33.50 at the 28 Oct 2026 close; market capitalisation ₹43.72 Cr; sector Healthcare. The share price rose 2.5% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 37.8% year on year to ₹15.3 Cr and net profit was −₹4.24 Cr, against −₹2.01 Cr a year earlier (compared with Jun 2025). Promoters held 70.60% of ANG Lifesciences in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 56/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹33.50 +2.00 +6.35% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹43.72 Cr
EBITDA
₹1.30 Cr
Return on Equity
-20.96%
Debt to Equity
1.49
Book Value
₹36.91
EPS (TTM)
−₹10.21
52W High
₹49.69
52W Low
₹17.63

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.8035.054,23,915 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,636.0087.462,55,806 Cr15.260.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,595.6072.141,74,802 Cr9.510.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,184.30107.921,18,020 Cr22.270.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.0026.281,17,805 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,341.0034.731,11,931 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.4032.831,10,709 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
ANG Lifesciences (this company)
——44 Cr0.913.00%-20.96%-8.47%84 Cr-13 Cr
Median 8 companies₹1,766.8035.051,17,913 Cr4.710.72%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

56 Good
Overall score

Data confidence 88/100

Category scores

Quality Good 58
Returns, margins, earnings quality 22% weight
Valuation Strong 89
Cheap vs sector & own history 24% weight
Growth Poor 18
Sales & profit trajectory 9% weight
Financial Health Poor 16
Solvency, leverage, coverage 9% weight
Momentum Strong 74
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Stock is trading at 0.93 times its book value

Weaknesses

5
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -9.66% over past five years.
  • Company has a low return on equity of -14.4% over last 3 years.
  • Promoters have pledged 44.9% of their holding.
  • Company has high debtors of 267 days.

Technical Indicators

Oscillators

Neutral

Bearish
2
Neutral
5
Bullish
2

Overall

Bearish

Bearish
10
Neutral
5
Bullish
4

Moving Averages

Bearish

Bearish
8
Neutral
0
Bullish
2

Growth Rate

Revenue Growth
-1.58% higher than 3Y

change over 1 year

Net Income Growth
-10.48% lower than 3Y

change over 1 year

Cash Flow Change
—

EBITDA Margin Change
-615%

change over 1 year Operating margin -12.75% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
56.46
33.26
18.55
37.84
18.41
32.88
24.73
16.82
24.6
26.05
18.73
23.5
15.3
Expenses
49.92
31.6
20.46
34.48
20.12
30.6
26.88
17.52
23.95
25.97
21.41
20.82
17.25
Operating Profit
6.54
1.66
-1.91
3.36
-1.71
2.28
-2.15
-0.7
0.65
0.08
-2.68
2.68
-1.95
OPM %
11.58%
4.99%
-10.3%
8.88%
-9.29%
6.93%
-8.69%
-4.16%
2.64%
0.31%
-14.31%
11.4%
-12.75%
Other Income
0.32
0.22
-0.03
-1.55
1.28
0.35
-0.27
0.65
0.09
0.12
0.16
0.17
0.11
Interest
2.31
2.29
2.51
3.84
2.08
2.18
2
2.42
1.94
1.89
1.93
2.18
2.24
Depreciation
2.19
2.22
1.91
2.05
1.63
1.74
1.96
1.42
1.53
1.52
1.51
1.77
1.5
PBT
2.36
-2.63
-6.36
-4.08
-4.14
-1.29
-6.38
-3.89
-2.73
-3.21
-5.96
-1.1
-5.58
Tax %
25.85%
-12.17%
-6.92%
-10.54%
-25.85%
62.02%
-18.65%
-47.04%
-26.74%
-8.41%
-20.3%
25.45%
-24.01%
Net Profit
1.75
-2.32
-5.93
-3.65
-3.07
-2.09
-5.19
-2.06
-2.01
-2.95
-4.75
-1.38
-4.24
EPS (₹)
1.34
-1.78
-4.54
-2.8
-2.35
-1.6
-3.97
-1.58
-1.54
-2.26
-3.64
-1.06
-3.25
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
154
354
220
145
93
93
84
Expenses
140
286
205
135
94
90
85
Operating Profit
14
68
15
10
-1
3
-2
OPM %
9%
19%
7%
7%
-1.6%
2.8%
-2.2%
Other Income
1
1
10
-1
2
-1
1
Interest
4
9
12
11
9
8
8
Depreciation
1
6
9
8
7
6
6
PBT
10
54
3
-11
-16
-13
-16
Tax %
31%
25%
110%
-5%
-21%
-15%
—
Net Profit
7
40
0
-10
-12
-11
-13
EPS (₹)
5.26
31.02
-0.2
-7.77
-9.5
-8.49
-10.21
Div. Payout %
0%
3%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
—
10
13
13
13
13
Reserves
—
73
73
63
51
40
Borrowings
—
77
71
73
83
79
Other Liabilities
—
130
119
92
82
78
Total Liabilities
—
290
276
241
230
210
Fixed Assets
—
93
88
58
57
51
CWIP
—
0
0
0
0
0
Investments
—
0
0
0
0
0
Other Assets
—
198
188
183
172
160
Total Assets
—
290
276
241
230
210
Figures in ₹ Crores

Cash Flow

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
25
26
-9
0
11
Investing
—
-44
-9
20
-2
1
Financing
—
20
-17
-10
2
-12
Net Cash Flow
—
0
0
0
0
0
Free Cash Flow
—
-17
16
9
-4
11
CFO/OP
—
37
202
39
-272
429
Figures in ₹ Crores

Ratios

Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
105
138
184
262
267
Inventory Days
—
59
118
183
331
288
Days Payable
—
113
165
254
405
317
Cash Conversion Cycle
—
51
91
113
189
238
Working Capital Days
—
20
24
58
72
-8
ROCE %
—
—
9%
1%
-4%
-2%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view ANG Lifesciences insights

63 extracted metrics + investor summaries across FY13–FY27.

Shareholding Pattern

Promot.70.60%Others2.98%Public26.42%As ofSep 2026
44.88% of promoter holding pledged as of 14 Oct 2026

Documents

Frequently Asked Questions about ANG Lifesciences

What does ANG Lifesciences India Ltd do?
Incorporated in 2006, ANG Lifesciences India Ltd is in the business of pharmaceuticals products & formulations, and packaging and printing.[1]
Where is ANG Lifesciences India Ltd (ANG) listed?
ANG Lifesciences India Ltd trades under code 540694 on the BSE.
Which sector does ANG Lifesciences India Ltd belong to?
ANG Lifesciences India Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd has a market capitalisation of ₹43.72 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of ANG Lifesciences India Ltd?
Over the last 52 weeks ANG Lifesciences India Ltd has traded between ₹17.63 and ₹49.69 as of 28 Oct 2026.
Does ANG Lifesciences India Ltd pay dividends?
ANG Lifesciences India Ltd has a dividend yield of 2.99%.
What is the Return on Equity (ROE) of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd reported a return on equity of -20.96%. Its debt-to-equity ratio is 1.49.

Company Information

Incorporated in 2006, ANG Lifesciences India Ltd is in the business of pharmaceuticals products & formulations, and packaging and printing.[1]

Website anglifesciences.com
Listed 2017-09-08
Face Value ₹ 10
Shares Outstanding 1,30,49,527

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540694.md for ANG Lifesciences India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month